Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenfu Yixin Granules (参附益心颗粒) is a Traditional Chinese Medicine (TCM) therapeutic developed by Shandong Buchang Pharmaceuticals for the treatment of cardiovascular conditions. The formulation is primarily indicated for chronic heart failure, specifically heart failure with reduced ejection fraction (HFrEF), and coronary heart disease, particularly in patients exhibiting the TCM "Yang Deficiency" pattern. Based on its name, the granules likely contain *Panax ginseng* (Ren Shen) and *Aconitum carmichaelii* (Fu Zi), which are traditionally used to restore Yang, tonify Qi, and improve cardiac output. The drug is currently undergoing Phase 2 clinical evaluation in China to assess its efficacy in improving cardiac function and symptoms in heart failure patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenfu Yixin Granules.